Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice

  • Peter Bramlage, Claudia Zemmrich, Ketelhut, Wolf-Peter Wolf, Eva Maria Fronk, Roland Schmieder
  • Vascular Health and Risk Management, August 2013, Taylor & Francis
  • DOI: 10.2147/vhrm.s49118

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Peter Bramlage